EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly

Chi Young Ok iD, Anuya Natu, Parnaz Daneshpajouhnejad, Lamiaa A Fathalla, Emily Symes, Paul Barone, Anna Shestakova, Kathryn K Foucar, Carlos Bueso-Ramos, Guillermo Montalban-Bravo iD, Attilio Orazi, Mrinal Patnaik und 6 weitere

Cancer · 2025

DOI: 10.1002/cncr.70176 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2025. Verfasst von Chi Young Ok und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myelomonocytic, Chronic. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic myelomonocytic leukemia (CMML) is largely a disease of individuals older than 50 years; its occurrence in patients aged 50 years and younger is rare. The authors sought to characterize the clinicopathologic features and genetic profile of young‐onset (age 50 years and younger) CMML (y‐CMML) compared with older onset (older than 50 years) CMML (o‐CMML).

Methods

The authors conducted a multi‐institutional study of 32 patients with y‐CMML and 119 patients with o‐CMML, analyzing clinical, morphologic, cytogenetic, and molecular data.

Results

Patients who had y‐CMML frequently presented with splenomegaly (59% vs. 11%; p < .001) and hepatomegaly (25% vs. 2%; p < .001) compared with those who had o‐CMML. Although the overall incidence of cytogenetic abnormalities was similar, patients who had y‐CMML exhibited distinct mutational patterns. PTPN11 mutations were significantly more common in y‐CMML (13% vs. 3%; p = .034) than in o‐CMML, whereas TET2 (6% vs. 57%; p < .001) and SRSF2 (16% vs. 46%; p = .002) mutations were significantly less frequent. In addition, multi‐hit TET2 (6% vs. 34%; p = .002) and TET2‐SRSF2 (3% vs. 29%; p = .003) co‐mutations were rare in y‐CMML. However, the molecular differences did not affect the CMML‐specific risk‐stratification categories because the clinical outcomes, including overall survival and leukemia‐free survival, did not differ between the two groups.

Conclusions

CMML in patients aged 50 years and younger is rare and presents with unique clinical and mutational features, suggesting a distinct pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelomonocytic, ChronicHumansMiddle AgedFemaleMaleAgedAdultMutationProtein Tyrosine Phosphatase, Non-Receptor Type 11DNA-Binding ProteinsAge of OnsetDioxygenasesProto-Oncogene ProteinsSerine-Arginine Splicing FactorsAged, 80 and overAge FactorsYoung Adult

Stichwörter der Autor:innen

SRSF2‐TET2 co‐mutationchronic myelomonocytic leukemia (CMML)multi‐hit TET2young

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11DNA-Binding ProteinsPTPN11 protein, humanDioxygenasesProto-Oncogene ProteinsTET2 protein, humanSerine-Arginine Splicing FactorsSRSF2 protein, human

Autor:innen und Institutionen

  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Department of Pathology, University of Chicago, Chicago, Illinois, USA.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.

ORCID-Profile: Chi Young Ok, Guillermo Montalban-Bravo

Zitieren

APA

Ok, C. Y., Natu, A., Daneshpajouhnejad, P., Fathalla, L. A., Symes, E., Barone, P., Shestakova, A., Foucar, K. K., Bueso-Ramos, C., Montalban-Bravo, G., Orazi, A., Patnaik, M., Hasserjian, R., Arber, D., Geyer, J. T., Bagg, A., Reichard, K. K., & Wang, S. A. (2025). Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly. Cancer. https://doi.org/10.1002/cncr.70176

Vancouver

Ok CY, Natu A, Daneshpajouhnejad P, Fathalla LA, Symes E, Barone P, et al. Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly. Cancer. 2025. doi:10.1002/cncr.70176

BibTeX
@article{Ok2025,
  author = {Ok, Chi Young and Natu, Anuya and Daneshpajouhnejad, Parnaz and Fathalla, Lamiaa A and Symes, Emily and Barone, Paul and Shestakova, Anna and Foucar, Kathryn K and Bueso-Ramos, Carlos and Montalban-Bravo, Guillermo and Orazi, Attilio and Patnaik, Mrinal and Hasserjian, Robert and Arber, Daniel and Geyer, Julia T and Bagg, Adam and Reichard, Kaaren K and Wang, Sa A},
  title = {Chronic myelomonocytic leukemia in the young (aged 50 years and younger): Divergent clinical and molecular characteristics from the elderly},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70176}
}
Kostenlos starten →